Cited by 208Per- and polyfluoroalkyl substances researchPeroxisome Proliferator-Activated ReceptorsEffects and risks of endocrine disrupting chemicals

In Vitro Activity of a Panel of Per- and Polyfluoroalkyl Substances (PFAS), Fatty Acids, and Pharmaceuticals in Peroxisome Proliferator-Activated Receptor (PPAR) Alpha, PPAR Gamma, and Estrogen Receptor Assays

Open access
Evans, Nicola, Conley, Justin M., Cardon, Mary, Hartig, Phillip, Medlock-Kakaley, Elizabeth, Gray, L. Earl·2022·Toxicology and Applied Pharmacology

Abstract

Data demonstrate numerous per- and polyfluoroalkyl substances (PFAS) activate peroxisome proliferator-activated receptor alpha (PPARα), however, additional work is needed to characterize PFAS activity on PPAR gamma (PPARγ) and other nuclear receptors. We utilized in vitro assays with either human or rat PPARα or PPARγ ligand binding domains to evaluate 16 PFAS (HFPO-DA, HFPO-DA-AS, NBP2, PFMOAA, PFHxA, PFOA, PFNA, PFDA, PFOS, PFBS, PFHxS, PFOSA, EtPFOSA, and 4:2, 6:2 and 8:2 FTOH), 3 endogenous fatty acids (oleic, linoleic, and octanoic), and 3 pharmaceuticals (WY14643, clofibrate, and the metabolite clofibric acid). We also tested chemicals for human estrogen receptor (hER) transcriptional activation. Nearly all compounds activated both PPARα and PPARγ in both human and rat ligand binding domain assays, except for the FTOH compounds and PFOSA. Receptor activation and relative potencies were evaluated based on effect concentration 20% (EC 20), top percent of max fold induction (pmax top), and area under the curve (AUC). HFPO-DA and HFPO-DA-AS were the most potent (lowest EC 20, highest pmax top and AUC) of all PFAS in rat and human PPARα assays, being slightly less potent than oleic and linoleic acid, while NBP2 was the most potent in rat and human PPARγ assays. Only PFHxS, 8:2 and 6:2 FTOH exhibited hER agonism >20% pmax. In vitro measures of human and rat PPARα and PPARγ activity did not correlate with oral doses or serum concentrations of PFAS that induced increases in male rat liver weight from the National Toxicology Program 28-d toxicity studies. Data indicate that both PPARα and PPARγ activation may be molecular initiating events that contribute to the in vivo effects observed for many PFAS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.taap.2022.116136

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Evans et al. (2022) found that in vitro measurements of PPARα and PPARγ activity in human and rat models did not correlate with the oral doses or serum concentrations of PFAS that were associated with increased liver weights in male rats in National Toxicology Program 28-day toxicity studies.

    “Interestingly, in vitro measurements of PPARα and PPARγ activity in human and rat models did not correlate with the oral doses or serum concentrations of PFAS that were associated with increased liver weights in male rats, as observed in National Toxicology Program 28-day toxicity studies [52].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Evans, N., Conley, J. M., Cardon, M., Hartig, P., Medlock-Kakaley, E., & Gray, L. E.
Affiliations
Environmental Protection Agency (US)
Corresponding author
Conley, Justin M.
Venue
Toxicology and Applied Pharmacology
Publisher
Elsevier BV
Published
2022-08
Volume
449
Pages
116136
ISSN
0041-008X (ISSN-L)
OpenAlex
W4283375803
Cited by
208
References
72
Citations by year
2026: 53 · 2025: 73 · 2024: 51 · 2023: 29 · 2022: 2
FWCI
13.73
Type
journal article
Language
en
Open access
Locations
  • Toxicology and Applied Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Topics
  • Physical Sciences › Environmental Science › Environmental Chemistry › Per- and polyfluoroalkyl substances research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Effects and risks of endocrine disrupting chemicals
Keywords
per- and polyfluoroalkyl substances, PPARα, PPARγ, estrogen receptor, nuclear receptor activation, HFPO-DA, fatty acids, clofibric acid, clofibrate, Wy-14,643, PFOS, PFHxS, molecular initiating events, liver weight, endocrine disruptors
MeSH terms
Animals, Fatty Acids, Female, Fluorocarbons, Ligands, Male, Receptors, Estrogen, PPAR alpha, PPAR gamma, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review